

Review Article

Concise Review: Are Stimulated Somatic Cells Truly Reprogrammed into an ES/iPS-Like Pluripotent State? Better Understanding by Ischemia-Induced Multipotent Stem Cells in a Mouse Model of Cerebral Infarction

Takayuki Nakagomi, Akiko Nakano-Doi, Aya Narita, and Tomohiro Matsuyama

Institute for Advanced Medical Sciences, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan

Correspondence should be addressed to Takayuki Nakagomi; nakagomi@hyo-med.ac.jp

Received 30 January 2015; Accepted 22 March 2015

Academic Editor: Kevin D. Bunting

Copyright © 2015 Takayuki Nakagomi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Following the discovery of pluripotent stem (PS) cells such as embryonic stem (ES) and induced pluripotent stem (iPS) cells, there has been a great hope that injured tissues can be repaired by transplantation of ES/iPS-derived various specific types of cells such as neural stem cells (NSCs). Although PS cells can be induced by ectopic expression of Yamanaka's factors, it is known that several stimuli such as ischemia/hypoxia can increase the stemness of somatic cells via reprogramming. This suggests that endogenous somatic cells acquire stemness during natural regenerative processes following injury. In this study, we describe whether somatic cells are converted into pluripotent stem cells by pathological stimuli without ectopic expression of reprogramming factors based on the findings of ischemia-induced multipotent stem cells in a mouse model of cerebral infarction.

1. Introduction

Reprogramming by ectopic expression of different transcription factors can induce conversion of adult mammalian somatic cells into various types of stem cells (e.g., induced pluripotent stem (iPS) cells by *c-myc*, *Klf4*, *Sox2*, and *Oct3/4* [1, 2]; neural stem cells (NSCs) by *c-myc*, *Klf4*, and *Sox2* [3]). However, increasing evidence has shown that reprogramming occurs in various organs during natural regenerative processes following injuries [4, 5]. Thus, it may be ideal if endogenous somatic cells can be converted into pluripotent stem (PS) cells under pathological conditions, thereby contributing to regeneration of damaged tissues.

Brain injuries such as ischemia/hypoxia promote the induction of endogenous NSCs [6]. Although the mechanism of NSC induction remains unknown, increasing evidence has shown that ischemia/hypoxia can increase stemness via reprogramming [7, 8]. In support of this idea, we recently showed that brain somatic cells such as pericytes (PCs) within ischemic regions developed stemness, thereby acquiring NSC

activity [9–11]. Brain-derived, ischemia-induced stem cells (iSCs) exhibited several PS cell markers such as *c-myc*, *Klf4*, *Sox2*, and *Nanog* and also showed their multipotency to differentiate into both neural and nonneural cell lineages, presumably through reprogramming [12]. However, it remains unclear whether iSCs can acquire traits similar to those of embryonic stem (ES) and iPS cells.

Recently, Takahashi et al. discovered that somatic cells such as fibroblast cells can be transformed into PS cells with phenotypes similar to ES cells by exogenous expression of Yamanaka's four factors: *c-myc*, *Klf4*, *Sox2*, and *Oct4* [1, 2]. Thus, if endogenous somatic cells can be successfully reprogrammed into PS cells in response to stimuli, they must express Yamanaka's four factors. In this study, we described whether stimulated somatic cells can indeed be converted into ES/iPS-like pluripotent state without ectopic expression of reprogramming factors. We focused on the expression of Yamanaka's four factors in iSCs extracted from poststroke adult mouse brains subjected to cerebral infarction.

2. What Is the Origin of iSCs?

In the adult mammalian brain, it is well known that NSCs are present in specific brain regions such as the subventricular zone and subgranular zone within the dentate gyrus of the hippocampus and that ongoing neurogenesis is retained in these two zones [13, 14]. Although precise phenotypes of NSCs remain unclear, various types of glial cell lineages such as radial glia [15], astrocytes in the subventricular zone [16], reactive astrocytes [6], resident glia [17, 18], and oligodendrocyte precursor cells [19] have been considered to be possible sources of NSCs.

NSCs are narrowly defined as stem cells that only give rise to neural cell lineages. However, increasing evidence shows that certain NSCs differentiate into both neural and nonneural lineages [20–22]. Thus, in a broad sense, NSCs are defined as multipotent stem cells that can differentiate into various lineages, including neural cells. Although the precise origin, identity, and subtype of such multipotent NSCs remain unclear, we recently demonstrated the development of injury-induced NSCs (iNSCs) within ischemic areas of poststroke brain, with a model of focal cortical infarction in adult mice. These iNSCs possessed self-renewal capacity, which was confirmed by 5-bromo-2'-deoxyuridine uptake. The iNSCs formed neurosphere-like cell clusters *in vitro* and differentiated into electrophysiologically functional neurons, astrocytes, and oligodendrocytes [23]. In addition, we have shown that iNSCs originate, at least in part, from reactive PCs within ischemic regions [9, 10] and that such PCs extracted from ischemic regions (iPCs) exhibited multipotency [12], consistent with the traits of PCs that have multilineage differentiation potential [24–31]. These findings indicate that, under pathological conditions, iPCs may be the origin of iSCs that give rise to iNSCs [9–12].

3. Are iSCs ES/iPS-Like Stem Cells?

iPC-derived iSCs expressed the NSC marker nestin as well as PC markers such as PDGFR β , NG2, and α SMA. In addition, iSCs formed cell clusters (Figure 1(a)) and displayed pluripotency markers *c-myc*, *Klf4*, and *Sox2* of Yamanaka's four factors (Figure 1(b)), as described previously [9, 12], which is consistent with the phenotypes of developing NSCs [32]. Furthermore, iSCs expressed the PS cell marker *Nanog*, although expression of *Nanog* as well as *Sox2* was weak compared with that of control ES cells. However, our previous study showed that iSCs isolated from adult mouse brain did not express *Oct4* by any method, including Western blot [9] and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses [12]. In addition, *Oct4* was not observed even after > 35 cycles of PCR amplification (Figure 1(b)), which should be able to detect very low levels of *Oct4* in tissue-committed stem cells such as very small embryonic-like stem cells (VSELs) [33]. The evidence that iSCs expressed *c-myc*, *Klf4*, and *Sox2*, but not *Oct4*, indicates that iSCs have different traits compared with that of PS cells such as ES/iPS cells. This also suggests that somatic cells in adult mouse brain have limited reprogramming potential in response to stimuli, thereby

acquiring less stemness compared with that of ES/iPS cells (Figure 2).

One critical question is whether PCs are indeed somatic cells because other groups have suggested that PCs originally possess stemness [24]. However, it is possible that such "naïve" PCs acquire stemness during *in vitro* treatment (e.g., repeated passages and chemical stimulation) because our studies showed that PCs in normal (nonischemic) areas rarely express Yamanaka's factors by immunohistochemistry and Western blot [9, 12]. Furthermore, we have never obtained PCs with stemness from nonischemic areas, which strongly suggests that under normal conditions, PCs in adult mice are initially somatic cells rather than tissue-committed stem cells. Even if PCs originally have a certain degree of stemness, our results still show that it is difficult for PCs in adult mouse brain to become ES/iPS-like stem cells by stimuli alone.

4. Why Do iSCs Express Reprogramming Factors following Ischemic Stroke?

iSCs could be easily isolated from ischemic areas but not nonischemic areas [9, 10, 12, 34, 35], showing that ischemia is essential for induction of iSCs. Ischemia is reported to activate the reprogramming factor *c-myc* following stroke [36]. Consistent with that study, using a mouse model of stroke, we have shown that *c-myc*⁺ cells were present within ischemic regions, including iSCs; however, they were rarely observed within nonischemic regions [12]. In addition, we showed that the reprogramming factors such as *Klf4* and *Sox2* were also expressed in iSCs within ischemic regions, whereas they were rarely expressed within nonischemic regions [12]. Furthermore, our study using commercially available primary human pericytes (hPCs) showed that under oxygen-glucose deprivation (OGD) conditions, which mimic ischemia/hypoxia *in vivo* [37], hPCs rapidly increased *Klf4* expression [12]. This suggests that OGD is a positive factor for inducing *Klf4* following ischemic stroke *in vivo*. However, OGD itself did not affect expression of *c-myc* in hPCs, although ischemic stroke increased expression of *c-myc* *in vivo*. In addition, we found that *Sox2* expression by OGD treatment was not as remarkable as *Klf4* expression, although *Sox2* was activated in iSCs following ischemic stroke [12].

These findings indicate that OGD itself cannot completely mimic ischemic events *in vivo* and that factors other than OGD are also involved in the activation of reprogramming factors in iSCs following ischemic stroke. In support of this idea, we found that environmental factors such as leukemia inhibitory factor [38] and basic fibroblast growth factor [39] that are secreted from stimulated endothelial cells surrounding PCs also function as positive factors for activation of *Sox2* [12]. These findings indicate that *in vivo* ischemia is a very complex event, and likely multiple factors, including OGD, are involved in the activation of reprogramming factors in iSCs following ischemic stroke. Additional studies are required to clarify which factors/signal pathways are critical to induction of iSCs.




FIGURE 1: iSCs were isolated from ischemic areas and formed cells clusters (a). iSCs as well as control ES cells expressed c-myc, Klf4, Sox2, and Nanog. However, Oct4 was not observed even after > 35 cycles of PCR amplification. The cycle number of PCR amplification is shown in the circles (b).

5. What Other Previously Reported Stem Cells Express Oct4 Other than ES/iPS Cells?

Although we have never detected Oct4 expression in iSCs, previous reports by other groups have shown Oct4 expression in several types of stem cells other than ES/iPS cells, such as VSELs [33, 40–43] and multilineage-differentiating

stress-enduring cells (muse cells) [44, 45]. Ratajczak and colleagues reported that VSELs are a population of developmentally early and small stem cells residing in adult tissues of both mice and humans [40, 42]. VSELs, defined by $\text{Lin}^- \text{Sca-1}^+ \text{CD45}^-$ markers, were reported to have phenotypes of PS cells. VSELs express PS cell markers such as stage-specific embryonic antigen (SSEA)-1, SSEA-4, Nanog, and even Oct4




FIGURE 2: Evidence that iSCs lacking Oct4 have different traits compared with those of ES/iPS cells, suggesting that somatic cells in adult mouse brains have limited reprogramming potential in response to stimuli.

[42, 46], although Oct4 expression in VSELs was very low compared with that of ES cells [33]. The population of quiescent VSELs expands in response to stimuli [43]. Until now, VSELs were reported to be isolated from various tissues, including bone marrow, testis, and ovary [33, 40, 41]. However, as far as we know, there has been no report of VSELs being obtained from brain. Thus, it is possible that Oct4 expression in stem cells is originally different among organs (e.g., between brains and bone marrow). However, recent studies by several independent researchers cast doubt on the presence of VSELs because they could not find Oct4-expressing PS cells in reported VSEL populations [47–49]. Therefore, the exact characteristics of VSELs should be clarified in further studies.

Muse cells are PS cells which belong to mesenchymal lineages and can be isolated from various tissues (e.g., bone marrow and skin) as SSEA-3/CD105 double-positive cells [44, 45]. In addition, muse cells are reported to express various PS cell markers, including Sox2, Nanog, and Oct4. However, Oct4 expression of muse cells was quite low compared with that of ES cells, and muse cells did not contribute to formation of teratoma-like tumorigenesis. Thus, it seems apparent that muse cells do not have the pluripotency to the degree observed in ES/iPS cells. Until now, muse cells expressing Oct4 can be successfully isolated from humans but not from other species. This also suggests that stemness is originally different among species (e.g., between mice and humans), although their precise traits remain unclear.

There have been many reports in which authors described that various types of stem cells such as mesenchymal stem cells [50, 51], adipose-derived stromal cells [52], and neural crest-derived stem cells [53–55] expressed Oct4. However, Bhartiya implied that some studies may have misinterpreted Oct4 expression [33]. Takeda et al. showed that Oct4 has two major isoforms, Oct4A and Oct4B, and only Oct4A is related to pluripotency, whereas Oct4B has no biological function [56]. Further, Warthemann et al. pointed out that it is possible that a false-positive for Oct4A expression may lead to misinterpretation [57]. Thus, stem cell biologists should carefully investigate Oct4 expression using appropriate positive controls such as ES/iPS cells because Oct4 is a key factor when estimating the state of pluripotency [1, 2, 58].

6. Conclusion

Herein, we discussed in detail whether stimulated somatic cells can acquire pluripotency. Our studies regarding iSCs showed they expressed *c-myc*, *Klf4*, and *Sox2*, but not *Oct4*, suggesting that even with severe stimuli, such as ischemia/hypoxia, which promote reprogramming, it is not easy to reprogram adult somatic cells into an ES/iPS-like state. Although iSCs lacked *Oct4*, pluripotency of iSCs should be carefully investigated because they certainly express various pluripotent markers such as *c-myc*, *Klf4*, *Sox2*, and *Nanog*, as we previously demonstrated [9, 12]. We need further examination regarding teratoma formation capacity and germline transmission ability. We also understand that further studies are required using younger mice (e.g., neonatal mice), various organs (e.g., bone marrow, liver, and lung), various stimuli (e.g., shear stress), and/or other species (e.g., rat and human). We hope that stem cell biologists would provide convincing answers for these fundamental questions in future investigations.

Abbreviations

ES cells:	Embryonic stem cells
iNSCs:	Ischemia-induced neural stem cells
iPCs:	Pericytes extracted from ischemic regions
iPS cells:	Induced pluripotent stem cells
iSCs:	Ischemia-induced stem cells
NSCs:	Neural stem cells
PCs:	Pericytes
PS cells:	Pluripotent stem cells
hPCs:	Human pericytes
VSELs:	Very small embryonic-like stem cells
SSEA:	Stage-specific embryonic antigen
RT-PCR:	Reverse transcriptase-polymerase chain reaction
OGD:	Oxygen-glucose deprivation.

Conflict of Interests

The authors declare that they have no conflict of interests.

References

- [1] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” *Cell*, vol. 126, no. 4, pp. 663–676, 2006.
- [2] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” *Cell*, vol. 131, no. 5, pp. 861–872, 2007.
- [3] M. Thier, P. Wörsdörfer, Y. B. Lakes et al., “Direct conversion of fibroblasts into stably expandable neural stem cells,” *Cell Stem Cell*, vol. 10, no. 4, pp. 473–479, 2012.
- [4] K. Yanger, Y. Zong, L. R. Maggs et al., “Robust cellular reprogramming occurs spontaneously during liver regeneration,” *Genes and Development*, vol. 27, no. 7, pp. 719–724, 2013.
- [5] A. Luz-Madrigo, E. Grajales-Esquivel, A. McCorkle et al., “Reprogramming of the chick retinal pigmented epithelium after retinal injury,” *BMC Biology*, vol. 12, article 28, 2014.
- [6] I. S. Shimada, B. M. Peterson, and J. L. Spees, “Isolation of locally derived stem/progenitor cells from the peri-infarct area that

- do not migrate from the lateral ventricle after cortical stroke," *Stroke*, vol. 41, no. 9, pp. e552–e560, 2010.
- [7] A. Mohyeldin, T. Garzón-Muvdi, and A. Quiñones-Hinojosa, "Oxygen in stem cell biology: a critical component of the stem cell niche," *Cell Stem Cell*, vol. 7, no. 2, pp. 150–161, 2010.
 - [8] Y. Yoshida, K. Takahashi, K. Okita, T. Ichisaka, and S. Yamanaka, "Hypoxia enhances the generation of induced pluripotent stem cells," *Cell Stem Cell*, vol. 5, no. 3, pp. 237–241, 2009.
 - [9] T. Nakagomi, Z. Molnár, A. Nakano-Doi et al., "Ischemia-induced neural stem/progenitor cells in the pia mater following cortical infarction," *Stem Cells and Development*, vol. 20, no. 12, pp. 2037–2051, 2011.
 - [10] T. Nakagomi, Z. Molnár, A. Taguchi et al., "Leptomeningeal-derived doublecortin-expressing cells in poststroke brain," *Stem Cells and Development*, vol. 21, no. 13, pp. 2350–2354, 2012.
 - [11] T. Nakagomi, A. Nakano-Doi, and T. Matsuyama, "Leptomeninges: a novel stem cell niche harboring ischemia-induced neural progenitors," *Histology and Histopathology*, vol. 30, pp. 391–399, 2015.
 - [12] T. Nakagomi, S. Kubo, A. Nakano-Doi et al., "Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells," *Stem Cells*, 2015.
 - [13] A. Alvarez-Buylla and J. M. García-Verdugo, "Neurogenesis in adult subventricular zone," *The Journal of Neuroscience*, vol. 22, no. 3, pp. 629–634, 2002.
 - [14] H. G. Kuhn, H. Dickinson-Anson, and F. H. Gage, "Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation," *Journal of Neuroscience*, vol. 16, no. 6, pp. 2027–2033, 1996.
 - [15] A. Kriegstein and A. Alvarez-Buylla, "The glial nature of embryonic and adult neural stem cells," *Annual Review of Neuroscience*, vol. 32, pp. 149–184, 2009.
 - [16] F. Doetsch, J. M. García-Verdugo, and A. Alvarez-Buylla, "Regeneration of a germinal layer in the adult mammalian brain," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 20, pp. 11619–11624, 1999.
 - [17] S. Belachew, R. Chittajallu, A. A. Aguirre et al., "Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons," *Journal of Cell Biology*, vol. 161, no. 1, pp. 169–186, 2003.
 - [18] W. D. Richardson, K. M. Young, R. B. Tripathi, and I. McKenzie, "NG2-glia as multipotent neural stem cells: fact or fantasy?" *Neuron*, vol. 70, no. 4, pp. 661–673, 2011.
 - [19] T. Kondo and M. Raff, "Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells," *Science*, vol. 289, no. 5485, pp. 1754–1757, 2000.
 - [20] M. Ii, H. Nishimura, H. Sekiguchi et al., "Concurrent vasculogenesis and neurogenesis from adult neural stem cells," *Circulation Research*, vol. 105, no. 9, pp. 860–868, 2009.
 - [21] K. Oishi and Y. Ito-Dufros, "Angiogenic potential of CD44⁺ CD90⁺ multipotent CNS stem cells in vitro," *Biochemical and Biophysical Research Communications*, vol. 349, no. 3, pp. 1065–1072, 2006.
 - [22] A. E. Wurmser, K. Nakashima, R. G. Summers et al., "Cell fusion-independent differentiation of neural stem cells to the endothelial lineage," *Nature*, vol. 430, no. 6997, pp. 350–356, 2004.
 - [23] T. Nakagomi, A. Taguchi, Y. Fujimori et al., "Isolation and characterization of neural stem/progenitor cells from post-stroke cerebral cortex in mice," *European Journal of Neuroscience*, vol. 29, no. 9, pp. 1842–1852, 2009.
 - [24] P. Dore-Duffy, A. Katychew, X. Wang, and E. van Buren, "CNS microvascular pericytes exhibit multipotential stem cell activity," *Journal of Cerebral Blood Flow & Metabolism*, vol. 26, no. 5, pp. 613–624, 2006.
 - [25] A. Birbrair, T. Zhang, Z.-M. Wang et al., "Skeletal muscle pericyte subtypes differ in their differentiation potential," *Stem Cell Research*, vol. 10, no. 1, pp. 67–84, 2013.
 - [26] A. Birbrair, T. Zhang, Z. M. Wang, M. L. Messi, A. Mintz, and O. Delbono, "Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle," *Frontiers in Aging Neuroscience*, vol. 6, article 245, 2014.
 - [27] A. Birbrair, T. Zhang, Z. M. Wang et al., "Type-2 pericytes participate in normal and tumoral angiogenesis," *The American Journal of Physiology—Cell Physiology*, vol. 307, pp. C25–C38, 2014.
 - [28] M. Karow, R. Sánchez, C. Schichor et al., "Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells," *Cell Stem Cell*, vol. 11, no. 4, pp. 471–476, 2012.
 - [29] M. J. Doherty, B. A. Ashton, S. Walsh, J. N. Beresford, M. E. Grant, and A. E. Canfield, "Vascular pericytes express osteogenic potential in vitro and in vivo," *Journal of Bone and Mineral Research*, vol. 13, no. 5, pp. 828–838, 1998.
 - [30] A. Dar, H. Domev, O. Ben-Yosef et al., "Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb," *Circulation*, vol. 125, no. 1, pp. 87–99, 2012.
 - [31] C. Farrington-Rock, N. J. Crofts, M. J. Doherty, B. A. Ashton, C. Griffin-Jones, and A. E. Canfield, "Chondrogenic and adipogenic potential of microvascular pericytes," *Circulation*, vol. 110, no. 15, pp. 2226–2232, 2004.
 - [32] J. B. Kim, H. Zaehres, G. Wu et al., "Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors," *Nature*, vol. 454, no. 7204, pp. 646–650, 2008.
 - [33] D. Bhartiya, "Are mesenchymal cells indeed pluripotent stem cells or just stromal cells? OCT-4 and VSELs biology has led to better understanding," *Stem Cells International*, vol. 2013, Article ID 547501, 6 pages, 2013.
 - [34] N. Nakagomi, T. Nakagomi, S. Kubo et al., "Endothelial cells support survival, proliferation, and neuronal differentiation of transplanted adult ischemia-induced neural stem/progenitor cells after cerebral infarction," *Stem Cells*, vol. 27, no. 9, pp. 2185–2195, 2009.
 - [35] A. Nakano-Doi, T. Nakagomi, M. Fujikawa et al., "Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction," *Stem Cells*, vol. 28, no. 7, pp. 1292–1302, 2010.
 - [36] T. Nakagomi, A. Asai, H. Kanemitsu et al., "Up-regulation of c-myc gene expression following focal ischemia in the rat brain," *Neurological Research*, vol. 18, no. 6, pp. 559–563, 1996.
 - [37] O. Hurtado, M. A. Moro, A. Cárdenas et al., "Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport," *Neurobiology of Disease*, vol. 18, no. 2, pp. 336–345, 2005.
 - [38] Y. Kubota, M. Hirashima, K. Kishi, C. L. Stewart, and T. Suda, "Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice," *The Journal of Clinical Investigation*, vol. 118, no. 7, pp. 2393–2403, 2008.
 - [39] J. Luo, F. Qiao, and X. Yin, "Hypoxia induces FGF2 production by vascular endothelial cells and alters MMP9 and TIMP1 expression in extravillous trophoblasts and their invasiveness in

- a cocultured model,” *Journal of Reproduction and Development*, vol. 57, no. 1, pp. 84–91, 2011.
- [40] M. Z. Ratajczak, D.-M. Shin, R. Liu et al., “Very Small Embryonic/Epiblast-Like stem cells (VSELs) and their potential role in aging and organ rejuvenation—an update and comparison to other primitive small stem cells isolated from adult tissues,” *Aging*, vol. 4, no. 4, pp. 235–246, 2012.
- [41] S. Parte, D. Bhartiya, J. Telang et al., “Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary,” *Stem Cells and Development*, vol. 20, no. 8, pp. 1451–1464, 2011.
- [42] M. Kucia, R. Reza, F. R. Campbell et al., “A population of very small embryonic-like (VSEL) CXCR4⁺SSEA-1⁺Oct-4⁺ stem cells identified in adult bone marrow,” *Leukemia*, vol. 20, pp. 857–869, 2006.
- [43] K. Grymula, M. Tarnowski, K. Piotrowska et al., “Evidence that the population of quiescent bone marrow-residing very small embryonic/epiblast-like stem cells (VSELs) expands in response to neurotoxic treatment,” *Journal of Cellular and Molecular Medicine*, vol. 18, no. 9, pp. 1797–1806, 2014.
- [44] Y. Kuroda, S. Wakao, M. Kitada, T. Murakami, M. Nojima, and M. Dezawa, “Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cells,” *Nature Protocols*, vol. 8, no. 7, pp. 1391–1415, 2013.
- [45] Y. Kuroda, M. Kitada, S. Wakao et al., “Unique multipotent cells in adult human mesenchymal cell populations,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 19, pp. 8639–8643, 2010.
- [46] M. Kucia, M. Halasa, M. Wyszczynski et al., “Morphological and molecular characterization of novel population of CXCR4⁺SSEA-4⁺Oct-4⁺ very small embryonic-like cells purified from human cord blood - Preliminary report,” *Leukemia*, vol. 21, no. 2, pp. 297–303, 2007.
- [47] K. Szade, K. Bukowska-Strakova, W. N. Nowak, A. Jozkowicz, and J. Dulak, “Comment on: the proper criteria for identification and sorting of very small embryonic-like stem cells, and some nomenclature issues,” *Stem Cells and Development*, vol. 23, no. 7, pp. 714–716, 2014.
- [48] K. Szade, K. Bukowska-Strakova, W. N. Nowak et al., “Murine bone marrow Lin⁻Sca-1⁺CD45⁻ very small embryonic-like (VSEL) cells are heterogeneous population lacking Oct-4A expression,” *PLoS ONE*, vol. 8, no. 5, Article ID e63329, 2013.
- [49] M. Miyanishi, Y. Mori, J. Seita et al., “Do pluripotent stem cells exist in adult mice as very small embryonic stem cells?” *Stem Cell Reports*, vol. 1, no. 2, pp. 198–208, 2013.
- [50] A. Poloni, G. Maurizi, P. Leoni et al., “Human dedifferentiated adipocytes show similar properties to bone marrow-derived mesenchymal stem cells,” *Stem Cells*, vol. 30, no. 5, pp. 965–974, 2012.
- [51] S. Roche, M.-J. Richard, and M.-C. Favrot, “Oct-4, Rex-1, and Gata-4 expression in human MSC increase the differentiation efficiency but not hTERT expression,” *Journal of Cellular Biochemistry*, vol. 101, no. 2, pp. 271–280, 2007.
- [52] Q. Gao, L. Zhao, Z. Song, and G. Yang, “Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs,” *Molecular Biology Reports*, vol. 39, no. 5, pp. 5791–5804, 2012.
- [53] S. Hauser, D. Widera, F. Qunneis et al., “Isolation of novel multipotent neural crest-derived stem cells from adult human inferior turbinate,” *Stem Cells and Development*, vol. 21, no. 5, pp. 742–756, 2012.
- [54] D. Pelaez, C.-Y. C. Huang, and H. S. Cheung, “Isolation of pluripotent neural crest-derived stem cells from adult human tissues by connexin-43 enrichment,” *Stem Cells and Development*, vol. 22, no. 21, pp. 2906–2914, 2013.
- [55] D. Widera, C. Zander, M. Heidbreder et al., “Adult palatum as a novel source of neural crest-related stem cells,” *Stem Cells*, vol. 27, no. 8, pp. 1899–1910, 2009.
- [56] J. Takeda, S. Seino, and G. I. Bell, “Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues,” *Nucleic Acids Research*, vol. 20, no. 17, pp. 4613–4620, 1992.
- [57] R. Warthemann, K. Eildermann, K. Debowski, and R. Behr, “False-positive antibody signals for the pluripotency factor OCT4A (POU5F1) in testis-derived cells may lead to erroneous data and misinterpretations,” *Molecular Human Reproduction*, vol. 18, no. 12, pp. 605–612, 2012.
- [58] D. C. Hay, L. Sutherland, J. Clark, and T. Burdon, “Oct-4 knock-down induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells,” *Stem Cells*, vol. 22, no. 2, pp. 225–235, 2004.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

